UNSPSC 51162719: Guaiacol phenylacetate

This classification denotes a topical anti-infective agent and expectorant with the molecular formula C15H14O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LLO759386W, chemically known as acetic acid, phenyl-, o-methoxyphenyl ester, but more generally known as guaiacol phenylacetate, which bears US NIH Compound Identifier 61331. European Medicines Agency schedules guaiacol phenylacetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14027MIG.

Most nations, for tariff purposes, schedule guaiacol phenylacetate under HS 29095000. SMILES: COC1CCCCC1OC(=O)CC2CCCCC2.

UNSPSC 51162719 Guaiacol phenylacetate is a Commodity code that in practice covers pharmaceutical and medical-supply procurement by state and local correctional, public-health, and emergency-response agencies. Recent state and local solicitations under this code center on parenteral nutrition solutions, intravenous products, naloxone, and drug-deactivation systems procured to support medically necessary healthcare in incarcerated populations and community health initiatives. The Washington State Department of Corrections and Seminole County, Florida are the primary recent buyers. Issuing bodies soliciting under this code include state corrections departments and county health and public-safety agencies; repeat buyers in the source are limited to the two named jurisdictions.

Activity under the code concentrates in Washington state and Florida based on recent postings. The Washington State Department of Corrections issued RFQ RFQQK13020 on September 8, 2026, with a response deadline of October 7, 2026, for parenteral products, services, and equipment (parenteral nutrition solutions, intravenous solutions, and controlled substances for medically necessary healthcare) to be supplied to eight correctional facilities across three regions, with DOC anticipating multiple awards of up to three bidders per region and an initial contract term running November 26, 2026 through June 30, 2030. The RFQ includes set-aside targets for small businesses (25%), minority-owned businesses (10%), women-owned businesses (6%), and veteran-owned businesses (5%), and requires prime contractors to submit a Subcontractor Inclusion Plan identifying qualified minority-owned, women-owned, and disadvantaged subcontractors where feasible. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, for annual procurement of 1,900 units of naloxone and 800 safe drug-deactivation systems with quarterly deliveries to the Seminole County Community Health Building, Sanford, Florida, with a response deadline of July 26, 2026.